Black Diamond Therapeutics (Black Diamond Therapeutics) Net Cash per Share : $1.73 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Black Diamond Therapeutics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Black Diamond Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 was $1.73.

The historical rank and industry rank for Black Diamond Therapeutics's Net Cash per Share or its related term are showing as below:

BDTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.8 Med: 1.42 Max: 3.94
Current: 3.49

During the past 7 years, the highest Price-to-Net-Cash Ratio of Black Diamond Therapeutics was 3.94. The lowest was 0.80. And the median was 1.42.

BDTX's Price-to-Net-Cash is ranked better than
54.46% of 863 companies
in the Biotechnology industry
Industry Median: 4.14 vs BDTX: 3.49

Black Diamond Therapeutics Net Cash per Share Historical Data

The historical data trend for Black Diamond Therapeutics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Black Diamond Therapeutics Net Cash per Share Chart

Black Diamond Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

Get a 7-Day Free Trial

-1.56

8.13

4.36

2.26

1.73

Black Diamond Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Cash per Share	Get a 7-Day Free Trial															2.26	1.81	1.42	2.06	1.73

Competitive Comparison of Black Diamond Therapeutics's Net Cash per Share

For the Biotechnology subindustry, Black Diamond Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's Price-to-Net-Cash falls into.

Black Diamond Therapeutics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Black Diamond Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(131.4	-	41.831	-	0)	/	51.6456
=	1.73

Black Diamond Therapeutics's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(131.4	-	41.831	-	0)	/	51.6456
=	1.73

Black Diamond Therapeutics (NAS:BDTX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Black Diamond Therapeutics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Black Diamond Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Black Diamond Therapeutics (Black Diamond Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Black Diamond Therapeutics Inc (NAS:BDTX) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Main Street, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.blackdiamondtherapeutics.com

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-189 and BDTX-1535.

Executives

Biotech Growth N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Ra Capital Nexus Fund, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali Behbahani	director, 10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter Kolchinsky	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David M. Epstein	director, officer: See Remarks	OSI PHARMACEUTICALS, INC., 41 PINELAWN ROAD, MELVILLE NY 11747
Sergey Yurasov	officer: CHIEF MEDICAL OFFICER	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310, SEATTLE WA 98102
Elizabeth Buck	officer: CHIEF SCIENTIFIC OFFICER	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Erika Jones	officer: SEE REMARKS	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Fang Ni	officer: SEE REMARKS	C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR, CAMBRIDGE MA 02142
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Wendy L Dixon	director
Mark A. Velleca	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Brent Hatzis-schoch	officer: See Remarks	C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451